EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bristol-Myers Squibb Co's Enterprise Value is $188,981 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $8,950 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBIT for today is 21.12.
The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-EBIT or its related term are showing as below:
BMY'
s EV-to-EBIT Range Over the Past 10 Years
Min: -70.86 Med: 21.01 Max: 126.73
Current: 21.03
During the past 13 years, the highest EV-to-EBIT of Bristol-Myers Squibb Co was 126.73. The lowest was -70.86. And the median was 21.01.
BMY's EV-to-EBIT is ranked worse than 62.74% of 671
companies
in the Drug Manufacturers industry
Industry Median: 15.94
vs BMY: 21.03
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Jun. 2022 was $194,232 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $8,950 Mil. Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was 4.61%.
Bristol-Myers Squibb Co EV-to-EBIT Historical Data
The historical data trend for Bristol-Myers Squibb Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Bristol-Myers Squibb Co Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-EBIT
18.93
13.51
31.12
-31.75
17.25
Bristol-Myers Squibb Co Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-EBIT
-66.31
-56.74
17.25
21.76
21.70
Competitive Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBIT falls into.
Bristol-Myers Squibb Co EV-to-EBIT Calculation
Bristol-Myers Squibb Co's EV-to-EBIT for today is calculated as:
Bristol-Myers Squibb Co's current Enterprise Value is $188,981 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,950 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (NYSE:BMY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Jun. 2022 was $194,232 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,950 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(0.55%) Volume: 5,302,688 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:BMY has been successfully added to your 
